<!DOCTYPE html>
<html lang="es">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Publicaciones - Javier Lanillos-Manchón</title>
    <link rel="stylesheet" href="../css/style.css">
    <style>
        /* Basic Dropdown Styling */
        .dropdown {
            background-color: #388e3c;
            color: white;
            padding: 10px;
            cursor: pointer;
            width: 100%;
            text-align: left;
            border: none;
            font-size: 18px;
        }

        .dropdown-content {
            display: none;
            background-color: #f4f4f4;
            padding: 10px;
            border-radius: 5px;
            margin-top: 10px;
        }

        .dropdown-content article {
            margin-bottom: 20px;
        }

        .dropdown-content a {
            color: #388e3c;
            text-decoration: none;
        }

        .dropdown-content a:hover {
            text-decoration: underline;
        }

        /* Optional: style to indicate expanded sections */
        .expanded {
            background-color: #2e7d32;
        }

        /* Change dropdown titles color */
        .dropdown {
            color: #388e3c;
        }
    </style>
</head>
<body>
    <header>
        <h1>Publications</h1>
        <nav>
            <ul>
                <li><a href="index.html">Introduction</a></li>
                <li><a href="pages/research.html">Research</a></li>
                <li><a href="pages/publications.html">Publications</a></li>
                <li><a href="pages/skills.html">Skills</a></li>
            </ul>
        </nav>
    </header>

    <main>
        <section>
            <h2>Publicaciones Científicas</h2>

            <!-- Dropdown for Highlighted Publications -->
            <button class="dropdown">Highlighted Publications</button>
            <div class="dropdown-content">
                <article>
                    <ul>
                        <li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6691382/">Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma</a></li>
                        <p>This study uncovers a miRNA signature linked to prognosis in metastatic pheochromocytoma/paraganglioma and identifies the miR-21-3p/TSC2/mTOR axis as a potential therapeutic target.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma</a></li>
                        <p>This research delineates the genomic alterations and immune profiles characteristic of metastatic pheochromocytoma and paraganglioma.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome</a></li>
                        <p>This study identifies mTOR pathway alterations in chromophobe renal cell carcinoma patients associated with unfavorable prognoses.</p>
                    </ul>
                </article>
            </div>

            <!-- Dropdown for Other Collaborations -->
            <button class="dropdown">Other Collaborations</button>
            <div class="dropdown-content">
                <article>
                    <ul>
                        <li><a href="#">Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing</a></li>
                        <p>This research highlights hsa-miR-139-5p as a prognostic marker in thyroid cancer, implicating its role in alternative splicing through HNRNPF.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">PTEN expression and mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with renal cell carcinoma</a></li>
                        <p>This study associates PTEN expression and mutations in TSC1, TSC2, and MTOR with the therapeutic response to rapalogs in renal cell carcinoma patients.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial</a></li>
                        <p>This clinical trial evaluates the efficacy of combining Sunitinib and Evofosfamide in treatment-naïve patients with metastatic pancreatic neuroendocrine tumors.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma</a></li>
                        <p>This research investigates the frequency of pathogenic germline variants in individuals diagnosed with metastatic renal cell carcinoma.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data</a></li>
                        <p>This study conducts a pharmacogenetic analysis on exome sequencing data from 5,001 individuals to inform personalized medicine approaches.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma</a></li>
                        <p>This case report identifies a novel germline DNMT3A mutation in a patient presenting with multiple paragangliomas and papillary thyroid carcinoma.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">CD133 expression in medullary thyroid cancer cells identifies patients with poor prognosis</a></li>
                        <p>This research associates CD133 expression in medullary thyroid cancer cells with poorer patient outcomes.</p>
                    </ul>
                </article>

                <article>
                    <ul>
                        <li><a href="#">Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition</a></li>
                        <p>This study demonstrates that loss of USP9X increases renal cancer cells' sensitivity to mTOR inhibitors.</p>
                    </ul>
                </
